Alligator Bioscience AB (LTS:0RK9)

kr 1.256 0 (0%) Market Cap: 934.77 Mil Enterprise Value: 869.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Q4 2023 Alligator Bioscience AB Earnings Call Transcript
Feb 09, 2024

kr1.16

Earnings
Q2 2023 Alligator Bioscience AB Earnings Call Transcript
Jul 13, 2023

kr0.380565 (-6.15%)

Earnings
Q1 2023 Alligator Bioscience AB Earnings Call Transcript
Apr 25, 2023

kr0.54311

Earnings
Q4 2022 Alligator Bioscience AB Earnings Call Transcript
Feb 10, 2023

kr0.733614

Earnings
Q3 2022 Alligator Bioscience AB Earnings Call Transcript
Oct 20, 2022

kr0.539375

Earnings
Alligator Bioscience AB at Redeye Growth Day (Virtual) Transcript
Jun 02, 2022
Q1 2022 Alligator Bioscience AB Earnings Call Transcript
Apr 27, 2022

kr0.758746

Earnings
Q4 2021 Alligator Bioscience AB Earnings Call Transcript
Feb 11, 2022

kr0.942198

Earnings
Q3 2021 Alligator Bioscience AB Earnings Call Transcript
Oct 22, 2021

kr0.730733

Earnings
Q2 2021 Alligator Bioscience AB Earnings Call Transcript
Jul 13, 2021

kr1.62

Earnings
Q4 2020 Alligator Bioscience AB Earnings Call Transcript
Feb 26, 2021

kr1.62

Earnings
Alligator Bioscience AB at Biostock Life Science Summit (Virtual) Transcript
Nov 18, 2020
Q3 2020 Alligator Bioscience AB Earnings Call Transcript
Oct 22, 2020

kr1.76

Earnings
Alligator Bioscience AB R&D Market Update Transcript
Aug 27, 2020
Alligator Bioscience AB at AACR Virtual Annual Meeting Transcript
Apr 27, 2020
Q4 2019 Alligator Bioscience AB Earnings Call Transcript
Feb 12, 2020

kr1.93

Earnings

Q4 2020 Alligator Bioscience AB Earnings Call Transcript

Feb 26, 2021 / 01:00PM GMT

Release Date Price: kr1.62

Transcript

Per NorlÃ;n

Alligator Bioscience AB - CEO

© -

Okay, thanks so much for the introduction. And I would like to welcome you all to this conference call, which will focus on our year-end report. Let's move to next slide, slide 2.

This is just to confirm, as usual the presentation does include some forward-looking statements.

With that, we go to the next slide, slide 3. So let's start with the agenda. I and Marie, will present with fourth quarter and year-end results 2020. We will also give a short pipeline updates and some outlooks for 2021. So the presentation will then be ended with a Q&A session. And with that, we can move to slide 4.

This is a summary of the key highlights in 2020. During the year, Alligator's increased our focus on clinical development, and to reach major clinical inflection points with selective programs. Our focus programs are ATOR-1017 and mitazalimab.

The decision to focus on ATOR-1017 and mita is based on their strong positioning. The positive data that supports a very competitive profile for the respective programs versus

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.